Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Date:9/22/2009

THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 2LBA).

Denosumab administered subcutaneously demonstrated superiority for both delaying the time to the first on-study skeletal related events (SREs) (fracture, radiation to bone, surgery to bone, or spinal cord compression) (hazard ratio 0.82, 95 percent CI: 0.71, 0.95), and delaying the time to first-and-subsequent SREs (hazard ratio 0.77, 95 percent CI:0.66, 0.89). Both results were statistically significant in this 34 month study. The median time to first on-study SRE was not reached for denosumab and therefore could not be estimated. The median time to first on-study SRE was 26.5 months for Zometa, the current standard of care.

"Up to 80 percent of patients with advanced breast cancer will develop bone metastases that are often associated with severe and painful bone complications, which are a serious concern for both patients and physicians," said Alison Stopeck, M.D., associate professor of Medicine, Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson, AZ, United States of America. "Denosumab was superior to Zometa in preventing skeletal related events and delayed worsening of bone pain. In addition, denosumab also presented some potential tolerability advantages for many patients, includin
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
2. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
3. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
4. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
5. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
6. Abbott HIV Test Demonstrates Earlier Disease Detection
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
9. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
10. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
11. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Germany , May 26, 2015 ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... ® (QCI™) bioinformatics content and software platform ... on genomic variants identified in next-generation sequencing (NGS). ... platform are in oncology, for somatic and hereditary ...
(Date:5/26/2015)... FL (PRWEB) May 26, 2015 ... Inc. have announced plans for the company’s first cellular ... 2015, followed by a full day, hands-on stem cell ... by J. Victor Garcia Gimenez, M.D., President of Therapeutic ... the medical community’s increasing interest in regenerative medicine and ...
(Date:5/26/2015)... San Diego, CA (PRWEB) May 26, 2015 ... Biopharma, announced the beginning of a long-term relationship ... works on behalf of its members to provide ... “I am extremely pleased to count VGP as ... to more arthritic dog patients nationwide. Concentrating and ...
(Date:5/26/2015)... TORONTO , May 26, 2015 /PRNewswire/ - Fluorinov ... appointment of Luke M. Beshar to its ... adding financial and pharmaceutical industry expertise as Fluorinov accelerates ... of the Fluorinov team, it is a pleasure to ... had a significant impact on the strategy, financial strength ...
Breaking Biology Technology:QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3
... Aug. 10, 2011 Genesis Biopharma, Inc. (OTC/BB: ... today announced it has signed a Cooperative Research ... Institute (NCI).  Under the terms of the five-year ... work with Steven A. Rosenberg, M.D., Ph.D., the ...
... Accuray Incorporated (Nasdaq: ARAY ), the premier ... to present at the Wedbush Life Sciences: Management Access Conference ... a.m. ET/6:10 a.m. PT. A live webcast of ... page of the Company,s Web site at http://www.accuray.com . ...
... YORK, Aug. 9, 2011 Reportlinker.com ... report is available in its catalogue: ... Market: Facilities, Test Volumes, and Sales ... http://www.reportlinker.com/p0591318/Global-Microbiology-Testing-Market-Facilities-Test-Volumes-and-Sales-Forecasts-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic This ...
Cached Biology Technology:Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3Global Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country 2
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/14/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has ... in Smart Mobile Devices " report to their ... a watershed year for fingerprint sensors in smartphones and ... gave fingerprint sensors a raison d,etre in the mobile ... a must-have feature in flagship smartphones. The ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... University of Jerusalem researchers of an additional role for a ... world-wide efforts to develop genetic regulation aimed at controlling many ... The molecule, known as Lysyl-tRNA synthetase (or LysRS in brief) ... where it has long been recognized for its contribution in ...
... to be able to ward off disease pathogens, immune cells ... each other. The working group around Professor Dr. Oliver Fackler ... Heidelberg University Hospital has discovered a mechanism in an animal ... Cell mobility is inhibited by the HIV Nef protein. The ...
... its workshop on freezing of human sperm, eggs and embryos ... embryos". The workshop provides a forum for clinicians and scientists ... Here a few of the new research findings ... announce: Vitrification of reproductive cells: the ...
Cached Biology News:How HIV cripples immune cells 2
...
...
... silica based spin filter membrane to isolate DNA ... band is cut from an agarose gel and ... gel slice is melted irreversibly in a high ... to the silica spin filter membrane and washed ...
...
Biology Products: